跳至主要内容
临床试验/ISRCTN30579828
ISRCTN30579828进行中(未招募)3 期

Fluconazole plus flucytosine vs fluconazole alone for cryptococcal antigen-positive patients identified through screening: a phase III randomised controlled trial

St George's, University of London0 个研究点目标入组 600 人开始时间: 2021年3月4日最近更新:
适应症

试验速览

阶段
3 期
状态
进行中(未招募)
入组人数
600

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Consecutive patients aged >18 years
  • 2. HIV-seropositive
  • 3. CD4 count of <100 cells/µl
  • 4. Serum/plasma Cryptococcal antigen (CrAg) test positive within the last 14 days
  • 5. Cerebrospinal fluid (CSF) CrAg test negative or lumbar puncture not done (declined)
  • 6. Willing to participate in the study

排除标准

  • Current exclusion criteria:
  • Initial exclusion criteria:
  • 1. Prior episode of cryptococcal meningitis
  • 2. Pregnancy (confirmed by urine or serum pregnancy test) or breastfeeding
  • 3. Previous serious reaction to flucytosine or fluconazole
  • 4. Already taking high-dose fluconazole treatment (800-1200 mg/day) for =1 week
  • 5. Contraindicated concomitant medications including cisapride and the class of antihistamines including terfenadine
  • 6. HIV-seronegative
  • 7. Clinical symptoms/ signs of symptomatic meningitis at any time since CrAg screening, i.e. a progressively severe headache OR a headache and marked nuchal rigidity OR a headache and vomiting OR seizures OR a Glasgow Coma Scale (GCS) score of <15
  • 8. Jaundice
  • 9. CSF positive for cryptococcal meningitis (i.e. positive microscopy with India Ink, culture, or CrAg test) at any time between the CrAg test and screening for eligibility, while the patient remained without clinical symptoms/ signs of meningitis as described in 7 (late withdrawal criterion)
  • Late exclusion criteria: (after randomisation and day 1 visit)
  • 10. DAIDS grade 4 abnormalities of platelets, neutrophil count or creatinine level on baseline bloods:
  • 10.1. Platelets <25,000 x 10^6/l
  • 10.2. Neutrophils <400 x10^6/l
  • 10.3. Creatinine > 3.5x upper limit of normal (with standardised ULN of 114 µmol/l, this
  • includes any creatinine level =400 µmol/l)
  • 11. Microbiological evidence of CM on CSF if full CSF results not present at randomisation (e.g. screening CSF CrAg negative but culture on same sample later returns positive for CM)
  • Previous exclusion criteria:
  • 1. Prior episode of Cryptococcal meningitis
  • 2. Pregnancy (confirmed by urine or serum pregnancy test) or breastfeeding
  • 3. Previous serious reaction to flucytosine or fluconazole
  • 4. Already taking high-dose fluconazole treatment (800-1200 mg/day) for =1 week
  • 5. Contraindicated concomitant medications including cisapride and the class of antihistamines including terfenadine
  • 6. HIV-seronegative
  • 7. Clinical symptoms/ signs of symptomatic meningitis at any time since CrAg screening, i.e. a progressively severe headache OR a headache and marked nuchal rigidity OR a headache and vomiting OR seizures OR a Glasgow Coma Scale (GCS) score of <15
  • 8. Jaundice
  • 9. CSF positive for Cryptococcal meningitis (i.e. positive microscopy with India Ink, culture, or CrAg test) at any time between the CrAg test and screening for eligibility, while the patient remained without clinical symptoms/ signs of meningitis as described in 7 (late withdrawal criterion)

研究者

相似试验

Effect trial: Treatment of cryptococcal... | 临床试验